Skip to main content
Retour
Watch Compare

Hepion Pharmaceuticals, Inc.

Qualité des données : 83%
Également cotée sous CTRVP OTC
HEPA
OTC Manufacturing Chemicals
0,05 €
▼ 0,01 € (-13,46%)
Cap. Boursière: 522 914,0
Prix
0,05 €
Cap. Boursière
522 914,0
Fourchette du Jour
0,05 € — 0,05 €
Fourchette 52 Semaines
0,03 € — 0,62 €
Volume
24
Ouverture 0,05 €
Moyenne 50J / 200J
0,05 €
7,02% below
Moyenne 50J / 200J
0,06 €
25,86% below

Quick Summary

Points Clés

Negative free cash flow of -3,27 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-232,48%
En dessous de la moyenne du secteur (-53,47%)
ROIC-90,05%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio10,77
Interest CoverageN/A

Valorisation

PE (TTM)
-0,06
Au-dessus de la moyenne du secteur (-1,47)
P/B Ratio0,16
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,1 -1,5
P/B 0,2 1,6
ROE % -232,5 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -8,28 M
ROE -232,48% ROA -200,78%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3,27 M
ROIC -90,05% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10,77
Interest Coverage N/A Asset Turnover N/A
Working Capital 3,39 M Tangible Book Value 3,32 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,06 Forward P/E N/A
P/B Ratio 0,16 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -625,63%
Market Cap 522 914,0 Enterprise Value 522 914,0
Per Share
EPS (Diluted TTM) -0,88 Revenue / Share N/A
FCF / Share -0,28 OCF / Share -0,28
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 39,52%
SBC-Adj. FCF -3,32 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — 0,0 0,0 0,0
Net Income -8,28 M -13,19 M -48,93 M -42,20 M -32,72 M
EPS (Diluted) -0,88 -107,35 -12,32 -0,59 -0,47
Gross Profit — — — — —
Operating Income -4,16 M -19,35 M -48,45 M -45,49 M -30,40 M
EBITDA — — — — —
R&D Expenses 445 512,0 11,85 M 35,64 M 33,27 M 20,40 M
SG&A Expenses — — — — —
D&A 30 758,0 30 758,0 67 131,0 77 461,0 86 073,0
Interest Expense — — 9 465,0 10 164,0 8 859,0
Income Tax -2,97 M -2,97 M -409 022,0 -2,88 M 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3,07 M 1,61 M 18,09 M 60,24 M 103,55 M
Total Liabilities 402 405,0 3,48 M 10,81 M 10,39 M 10,56 M
Shareholders' Equity 2,67 M -1,86 M 7,28 M 49,86 M 93,00 M
Total Debt — — — — —
Cash & Equivalents — — — — —
Current Assets 3,07 M 1,61 M 17,49 M 56,50 M 97,45 M
Current Liabilities 299 383,0 3,14 M 5,29 M 7,89 M 8,21 M